We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.51 | 0.73% | 70.64 | 70.64 | 70.65 | 70.67 | 70.16 | 70.43 | 2,703,629 | 17:14:03 |
From Apr 2019 to Apr 2024
By Cecilia Butini
AstraZeneca PLC said Wednesday that the U.S. District Court for the Northern District of West Virginia has decided in its favor in litigation regarding patents protecting its asthma medication Symbicort.
Litigation was against Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery LP and was initiated with claims of infringement of various U.S. patents covering Symbicort, the British pharmaceutical giant said.
A third company, 3M Co., was initially part of the lawsuit but later dismissed from the case, AstraZeneca said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 03, 2021 02:34 ET (07:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
